Key facts: Biogen to release tau drug data; Morgan Stanley raises target; Jefferies hints at Nasdaq 100 removal
I'm PortAI, I can summarize articles.
Biogen will release data next year on a new drug targeting tau, part of its Alzheimer's research, aligning with the industry's push for therapies addressing multiple disease drivers.1Morgan Stanley has raised its price target for Biogen (BIIB) to $156.00 per share, an increase from the previous target of $149.00.2Jefferies reports Biogen may be removed from the Nasdaq 100 index due to low market cap. An announcement is expected after market close on Friday, effective December 22.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments